ISPAD clinical practice consensus guidelines 2022: Stages of type 1 diabetes in children and
adolescents Page 1 ISPAD GUIDELINES ISPAD clinical practice consensus guidelines 2022 …

Type 1 diabetes (T1D) is an autoimmune disease in which T cells attack and destroy the
insulin-producing β cells in the pancreatic islets. Genetic and environmental factors increase …

Background Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved
by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) …

Background Janus kinase (JAK) inhibitors, including baricitinib, block cytokine signaling and
are effective disease-modifying treatments for several autoimmune diseases. Whether …

We analyzed the effects of a single 14-day course of teplizumab treatment on metabolic
function and immune cells among participants in a previously reported randomized …

Nowadays, diabetes mellitus has emerged as a significant global public health concern with
a remarkable increase in its prevalence. This review article focuses on the definition of …

Importance In preclinical studies, thioredoxin-interacting protein overexpression induces
pancreatic beta cell apoptosis and is involved in glucotoxicity-induced beta cell death …

Type 1 diabetes is an autoimmune disease caused by the immune-mediated destruction of
pancreatic β cells that results in lifelong absolute insulin deficiency. For nearly a century …

In type 1 diabetes, insulin remains the mature therapeutic cornerstone; yet, the increasing
number of individuals developing type 1 diabetes (predominantly children and adolescents) …

Despite major advances over the past decade, prevention and treatment of type 1 diabetes
mellitus (T1DM) remain suboptimal, with large and unexplained variations in individual …